{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL7ys5oJDA","lastupdate":"2021-01-17T00:00:00.000Z","update_date":"2021-01-17T00:00:00.000Z","lastModified":"Sep 28, 2024","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"neurim-pharmaceuticals","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$5oxCx5fOvJh6PcK25Sq3y0O4PBbRmDKjzd7J2Lb010FeNfkzhUCzQh","name":"Neurim Pharmaceuticals","oneliner":"New Chemical Entities for Insomnia and Alzheimer's Disease","registrar":"512705203","website":"https://neurim.com","careerspage":"","founded_month":6,"founded_year":1991,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/1268772","instagram":""},"social":["https://www.linkedin.com/company/1268772"],"flattenedsociallinks":"https://www.linkedin.com/company/1268772","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":20,"patent":1,"raised":0,"stage":"Mature","public_stage":"Mature","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support. Its products are aimed at addressing insomnia, problems related to the central nervous system, and neurodegenerative diseases.\r\nThe company's first approved drug is Circadin, a timed-release melatonin for insomnia. Circadin is commercially available in Europe, the AsiaPacific region, and the Middle East.\r\nThe Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing authorization for Slenyto, a pediatric prolonged-release melatonin-coated tablet formulation for the treatment of children and adolescents with autism spectrum disorder and/or Smith-Magenis syndrome who suffer from insomnia.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97237684911","country":null,"address":{"israeli":[{"id":"d1e44132-bbd0-426a-85d5-3d03be39bf1d","city":"Tel Aviv-Yafo","type":null,"address":"HaBarzel Street 27, Tel Aviv, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"e46b2c52-3d2d-400b-b701-84465ccc8b8a","city":"Zug","address":"Baarerstrasse 135, Zug, Switzerland","country":"Switzerland","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"nWoy870GlzEbZrMQ7qs3uRu5KBU1jYlfisB4l4qKwCV3URCCNli70j","date":"Sep 10, 2025","link":"https://www.prnewswire.com/il/news-releases/health-canada-approves-slenyto-r-extended-release-melatonin-formulation-as-a-prescription-drug-for-insomnia-in-children-with-autism-spectrum-disorder-and-smith-magenis-syndrome-803852156.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"approval","round":null,"company":"Neurim Pharmaceuticals","layoffs":null,"summary":"Neurim Pharmaceuticals has received marketing authorization from Health Canada for Slenyto®, an extended-release melatonin minitablet designed for treating insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and Smith-Magenis syndrome (SMS). This approval marks a significant advancement in pediatric sleep medicine in Canada, addressing a critical unmet need for this population. Slenyto® is the first pharmacotherapy specifically developed and clinically tested for insomnia in children with these conditions. The product has demonstrated significant improvements in sleep latency, total sleep time, and sleep continuity, with a favorable safety profile. Neurim Pharmaceuticals aims to ensure broad access to Slenyto® across Canada through pediatric specialists, sleep clinics, and pharmacies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Slenyto","insomnia","children","ASD","Canada"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"YBjCguDJBe6rIdCTaKn8p3ljvtjTY6VKwTSzubVekFNoNSDtbB4hdY","news_summary":"/CNW/ -- Neurim Pharmaceuticals is pleased to announce that Health Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ONPtqelCqnMuxlug4LEh53CSKjzjbJbRkvSV31l6FNv6phZxpq0ThV","date":"Sep 10, 2025","link":"https://www.prnewswire.com/il/news-releases/health-canada-approves-slenyto---extended-release-melatonin-formulation---as-a-prescription-drug-for-insomnia-in-children-with-autism-spectrum-disorder-and-smith-magenis-syndrome-302552663.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["approval","pediatric"],"round":null,"company":"Neurim Pharmaceuticals","layoffs":null,"summary":"Neurim Pharmaceuticals has received marketing authorization from Health Canada for Slenyto®, an extended-release melatonin minitablet designed to treat insomnia in children and adolescents with Autism Spectrum Disorder (ASD) and Smith-Magenis syndrome (SMS). This approval marks a significant advancement in pediatric sleep medicine, offering a clinically proven and well-tolerated treatment for children with ASD affected by chronic sleep disturbances. Slenyto® is the first pharmacotherapy specifically developed and approved for insomnia in this population, addressing a critical unmet medical need. The product will soon be available in Canada through pediatric specialists, sleep clinics, and pharmacies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Slenyto","insomnia","autism","Canada","approval"],"date_of_event":"October 2023","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9qQgQvaJydcr0rtzVquXKwg0hk8NlgEqEfIvbUtdpplj1sSDhtJuni","news_summary":"/PRNewswire/ -- Neurim Pharmaceuticals is pleased to announce that Health Canada has granted marketing authorization* for Slenyto®, an Extended-release...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"608342fc-4090-40e4-95fc-bc43374d2e2d","date":"Feb 27, 2020","link":"https://www.spectrumnews.org/news/melatonin-may-ease-autistic-childrens-sleep-troubles/","source":"www.spectrumnews.org","visible":1,"analysis":{"tags":"Sleep Aid","company":"N/A","layoffs":"N/A","summary":"A new study suggests that melatonin is safe for long-term use in autistic children who have difficulty sleeping. The study tracked the effects of melatonin on autistic children over a two-year period and found that it can improve sleep and overall quality of life. The study also addressed concerns about the hormones long-term safety, particularly in regard to puberty, and found that melatonin does not interfere with puberty. The study adds to the growing evidence that melatonin is safe and effective for children with autism. However, it is important to have a regulated version of melatonin in the U.S. that is backed by data, as the current over-the-counter supplements vary in quality and dosage.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Melatonin","Autistic children","Sleep","Long-term safety","Puberty"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"7vEy8EhGFJX1V6joOqP59PTCJGasMJXp8bH2fR0OyfqZ6786ZHtJJY","news_summary":"Melatonin may ease autistic children's sleep troubles","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3e612fb5-b031-4e51-b5dc-f3abba039f27","date":"Jul 30, 2018","link":"https://www.prnewswire.com/news-releases/neurim-pharmaceuticals-receives-positive-chmp-opinion-for-slenyto-pediatric-prolonged-release-melatonin-for-the-treatment-of-insomnia-in-children-with-autism-spectrum-disorder-asd-300688436.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"pediatric insomnia","company":"Neurim Pharmaceuticals","layoffs":null,"summary":"Neurim Pharmaceuticals has received a positive opinion from the CHMP for its pediatric prolonged-release melatonin coated tablets formulation, Slenyto, for the treatment of children and adolescents with ASD and/or Smith-Magenis Syndrome who suffer from insomnia. The recommendation is based on comprehensive data demonstrating the efficacy and safety of Slenyto in addressing the unmet need for ASD children with impaired sleep. If approved, Slenyto would be the only approved medicinal product for sleep disorders in pediatric ASD patients. Insomnia disproportionately affects children with ASD, and currently, there is no approved treatment for insomnia in this population.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Slenyto","pediatric insomnia","ASD","melatonin","CHMP"],"date_of_event":"2018-07-30","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"scuWLpQOBXm4rnPPghAQC8RoRke3vMTOZFsh0KPy7Nqi66y9PXHj4n","news_summary":"Neurim Pharmaceuticals Receives Positive CHMP Opinion for Slenyto (Pediatric Prolonged-Release Melatonin) for the Treatment of Insomnia in Children With Autism Spectrum Disorder (ASD)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e72e7085-46af-47b6-8ea4-28da983ef83f","date":"Mar 29, 2017","link":"http://www.prnewswire.com/news-releases/neurim-pharmaceuticals-grants-exeltis-marketing-rights-for-paediatric-prolonged-release-melatonin-pedprm-in-spain-617436113.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["license agreement","pediatric insomnia","sleep medication","Neurology"],"company":"Neurim Pharmaceuticals","layoffs":null,"summary":"Neurim Pharmaceuticals has entered into a license agreement with Exeltis, granting Exeltis exclusive marketing rights for Neurims new Rx PedPRM in Spain. PedPRM is a sleep medication designed to treat sleep disorders in children with Autism Spectrum Disorders and neurogenetic diseases. The collaboration with Exeltis will increase the accessibility of the drug to children and their families. Neurim Pharmaceuticals focuses on making PedPRM commercially available in all markets. Exeltis, a division of Chemo Group, specializes in insomnia and has a presence in Neurology. The agreement reinforces their partnership, which began with the licensing of Circadin in Spain.","partners":["Exeltis"],"customers":null,"investors":null,"confidence":8,"key_topics":["license agreement","pediatric insomnia","sleep medication","Neurology","drug development"],"date_of_event":"March 29, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8IbtFBfyqEd9jNwKY3905Vg1ar75fjpTJQvIi198AGvV5CTvRGnd8J","news_summary":"Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (\"PedPRM\") in Spain","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3f41ab3c-ac83-4d41-9a58-db83d3ded866","date":"Jun 23, 2014","link":"http://www.globes.co.il/en/article-neurim-pharma-reports-success-in-alzheimers-disease-trial-1000948582","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug effectiveness","company":"Neurim Pharmaceuticals","layoffs":null,"summary":"Neurim Pharmaceuticals has completed an initial efficacy trial for its drug Circadin, which is currently used to treat sleep disorders, to determine its effectiveness in treating early-stage Alzheimers disease. The trial involved 80 patients with Alzheimers, with half receiving Circadin in addition to their regular treatment. The results showed that the group treated with Circadin had significantly fewer Alzheimers symptoms compared to the control group. Neurim Pharmaceuticals was founded by Prof. Nava Zisapel and is currently sold in 40 countries. The companys main investors are Nava and Yehuda Zisapel.","partners":["Lundbeck"],"customers":null,"investors":"Nava and Yehuda Zisapel","confidence":9,"key_topics":["Circadin","Alzheimers disease","sleep disorders","melatonin","clinical trial"],"date_of_event":"June 23, 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WtEoq1XjeurT9ckg981eh49sF28EseP1CeU3bkJma3m6FscQI5G3MX","news_summary":"Neurim Pharma reports success in Alzheimer's disease trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[],"tags":["neurology","degenerative-diseases","drug-discovery","sleep-disorders","alzheimers-disease","pharmaceuticals","cns-disorders","patients","pharma-companies","biopharmaceutical","seniors"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":["SLENYTO","PedPRM","Circadin","Piromelatine"],"geomarkets":["Asia","Europe","South Korea","Africa"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Mature","totalfunding":"Undisclosed","publicinvestors":1,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Nava Zisapel","email":"navaz@neurim.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgN6bmaEIDA","bounced":false,"claimed":0,"founder":1,"urlname":"nava-zisapel-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAscXgowsM","position":"Co-Founder  CSO","last_name":"Zisapel","claimtoken":"b2c6ae52f2d134098ee382938f9ea63a766ac04b99446ed8208302051aefbd8f","first_name":"Nava","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/nava-zisapel-8960386/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2021-01-17 11:49:59.000000","initials":"NZ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Adi  Melcer","email":"adim@neurim.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoO2OkZYKDA","bounced":false,"claimed":0,"founder":0,"urlname":"adi-melcer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgncaR9QoM","position":"Regional Sales & Marketing Manager","last_name":"Melcer","claimtoken":"d01e5a913b402e8b1d84f701ef1b013f1246e769ca2d6b7c6f082f0c651f8869","first_name":"Adi ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/adi-melcer-35a554135/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-01-17 11:49:52.000000","initials":"AM","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-04-03T00:00:00.000Z","crunchbaseid":"neurim-pharmaceuticals","lastupdator":"Orli Wollner","lastupdator_email":"orlushka@gmail.com","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2015-01-13T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7qXxCgw","date":"Jan 2000","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Prof. Nava & Yehuda Zisapel","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/prof-nava-yehuda-zisapel","logokey":null,"tagline":"","urlname":"/company_page/prof-nava-yehuda-zisapel","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qJCAw","fundingtype":"Other","leadpartner":null,"investmentid":"f9bfa053-ce4a-46d0-a06a-8dbfda01ad5b","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/1991","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Neurim Pharmaceuticals","logourl":"https://storage.googleapis.com/clean-finder-353810/$5oxCx5fOvJh6PcK25Sq3y0O4PBbRmDKjzd7J2Lb010FeNfkzhUCzQh","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$5oxCx5fOvJh6PcK25Sq3y0O4PBbRmDKjzd7J2Lb010FeNfkzhUCzQh","seoabout":"Neurim Pharmaceuticals is a drug discovery and development company focused on creating drugs for brain restoration and ongoing support. Its products are ai...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Biomaterials & Tissue Engineering#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"},{"title":"Biomaterials & Tissue Engineering","key":"0-0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Biomaterials & Tissue Engineering"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Biomaterials & Tissue Engineering","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4MeNluQIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development","Biomaterials & Tissue Engineering"],"coreTechnology":["Materials & Substances"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCE7qXxCgw","date":"Jan 2000","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Prof. Nava & Yehuda Zisapel","type":"Other","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/prof-nava-yehuda-zisapel","logokey":null,"tagline":"","urlname":"/company_page/prof-nava-yehuda-zisapel","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEv8qJCAw","fundingtype":"Other","leadpartner":null,"investmentid":"f9bfa053-ce4a-46d0-a06a-8dbfda01ad5b","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/startups-icon.svg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}